Geller Professor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

by Barry Teater, NCBiotech writer — February 16, 2021 . RESEARCH TRIANGLE PARK – After 13 years as a clinical-stage oncology company, G1 Therapeutics of Research Triangle Park transformed into a commercial-stage company overnight upon the approval of its first drug by the U.S. Food and Drug Administration. The FDA on Feb. 12 approved G1’s trilaciclib, to be marketed as Cosela, for protecting bone marrow from chemotherapy damage in adult patients with extensive-stage small cell lung cancer (ES-SCLC). “Cosela will help change the chemotherapy experience for people who are battling ES...

  After 13 years as a clinical-stage oncology company, G1 Therapeutics of Research Triangle Park transformed into a commercial-stage company overnight upon the approval of its first drug by the U.S. Food and Drug Administration. The FDA on Feb. 12 approved G1’s trilaciclib, to be marketed as Cosela, for protecting bone marrow from chemotherapy damage in adult patients with extensive-stage small cell lung cancer (ES-SCLC).  “Cosela will help change the chemotherapy experience for people who are battling ES-SCLC,” said Jack Bailey, the company’s chief executive officer. “G1 is prou...

FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression February 12, 2021 19:41 ET | Source: G1 Therapeutics G1 Therapeutics - COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small cell lung cancer being treated with chemotherapy - - Myeloprotective efficacy of COSELA resulted in reductions in the incidence and duration of severe neutropenia, and impacted anemia and the nee...